Clinical Trial Update: 14-day Double Therapy Versus Bismuth Quadruple Therapy in First-line Treatment of Helicobacter Pylori Infection [Phase 4]

View source ↗

Summary

Phase 4 trial comparing 14-day double therapy to bismuth quadruple therapy as first-line treatment for Helicobacter pylori infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Helicobacter Pylori Infection

Snippet

Sponsor: Shandong University | Conditions: Helicobacter Pylori Infection | Phase 4 | Status: UNKNOWN